ketamine P.O. - Psychedelic Institute -- Psychedelics in Mental Health

ketamine

Spotlight: Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis (Silberbauer, et al, 2025)

Treatment was well-tolerated, with no serious adverse events reported...in a total of 592 patients, meta-analysis of randomized controlled trials on oral ketamine treatment demonstrated its antidepressant efficacy with a Number Needed to Treat = 4.89 for response and a NNT = 9.16 for remission.

17 Oct

at home ketamine

Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)

"Findings suggested that racemic ketamine (including by mouth), when appropriately dosed and administered within a structured clinical and safety monitoring framework, is both effective, safe and well-tolerated over a 6-month treatment period."

10 Oct